Brief Introduction:

• National Medical Insurance, Category B;

• Launched in 1997,

• The first China-made Molgramostim in market,

• National standard bulk supplier of Molgramostim,

• As an important immunomodulator of tumor vaccines, Topleucon^® has participated in international clinical research in Europe in recent years. The relevant research results have been published on international authoritative tumor research platforms such as American Society of Clinical Oncology (ASCO) Annual Meeting.

Indications:
1.Treatment and prevention of leukopenia caused by radiotherapy or chemotherapy,
2.Treatment of bone marrow hematopoietic dysfunction and myelodysplastic syndrome,
3.Prevention of potential infection complications caused by leukopenia,
4.Accelerating recovery of neutrophils caused by infection
For details, please refer to Instructions.